Rhumbline Advisers Sells 6,726 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Rhumbline Advisers lessened its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 200,934 shares of the life sciences company’s stock after selling 6,726 shares during the quarter. Rhumbline Advisers owned 0.26% of Integra LifeSciences worth $4,557,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of IART. Empowered Funds LLC bought a new stake in Integra LifeSciences during the fourth quarter worth $180,000. Choreo LLC lifted its holdings in shares of Integra LifeSciences by 29.9% in the fourth quarter. Choreo LLC now owns 22,274 shares of the life sciences company’s stock worth $500,000 after buying an additional 5,123 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Integra LifeSciences by 599.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock worth $74,000 after purchasing an additional 2,800 shares during the period. Mitsubishi UFJ Asset Management UK Ltd. purchased a new position in shares of Integra LifeSciences during the fourth quarter worth about $204,000. Finally, Romano Brothers AND Company purchased a new stake in Integra LifeSciences during the fourth quarter valued at about $204,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Insider Buying and Selling at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the transaction, the executive vice president now directly owns 56,182 shares in the company, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 3.10% of the company’s stock.

Integra LifeSciences Price Performance

IART stock opened at $23.06 on Friday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences Holdings Co. has a 1 year low of $16.81 and a 1 year high of $41.17. The firm has a 50-day moving average of $23.77 and a 200 day moving average of $21.85. The company has a market cap of $1.78 billion, a P/E ratio of -256.19, a PEG ratio of 0.73 and a beta of 1.17.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. During the same quarter in the prior year, the company earned $0.89 EPS. The business’s revenue was up 11.5% compared to the same quarter last year. On average, sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Morgan Stanley began coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price target for the company. Citigroup increased their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $23.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.